CCR7 and neoplasm: Specifically, induction of CCR7 expression on cDC1s endows them with the ability to migrate to (tumor-draining) lymph nodes (tdLNs), and this is the mechanism by which CD4+ T-cell help delivered in the TME can lead to the availability of “helped/licensed” cDC1s bearing tumor antigens in tdLNs, which can help perpetuate the cancer immunity cycle [64].